Prostate-specific membrane antigen-PET has become a valuable diagnostic tool. The second version of the Prostate Cancer Molecular Imaging Standardized Evaluation framework is the next step towards a standardized evaluation and reporting system from primary staging to reassessment of advanced prostate cancer.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Maurer, T., Eiber, M., Schwaiger, M. & Gschwend, J. E. Current use of PSMA-PET in prostate cancer management. Nat. Rev. Urol. 13, 226–235 (2016).
European Association of Urology. EAU, EANM, ESTRO, ESUR, ISUP, SIOG Guidelines on Prostate Cancer. EAU https://uroweb.org/guideline/prostate-cancer (2023).
Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).
Roberts, M. J. et al. Using PSMA imaging for prognostication in localized and advanced prostate cancer. Nat. Rev. Urol. 20, 23–47 (2023).
Fanti, S. et al. Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. Eur. J. Nucl. Med. Mol. Imaging 44, 1622–1635 (2017).
Rowe, S. P., Pienta, K. J., Pomper, M. G. & Gorin, M. A. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J. Nucl. Med. 59, 479–485 (2018).
Eiber, M. et al. Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. J. Nucl. Med. 59, 469–478 (2018).
Fanti, S. et al. Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 48, 469–476 (2021).
Gafita, A. et al. Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study. J. Nucl. Med. 63, 1651–1658 (2022).
Seifert, R. et al. Second version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). Eur. Urol. 83, 405–412 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Koehler, D. PROMISE V2 — something new, something old and something borrowed. Nat Rev Urol 20, 639–640 (2023). https://doi.org/10.1038/s41585-023-00807-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-023-00807-1